• From WecA Kinetics to Translational Strategy

  2026-10-05

  A translational perspective on WecA as a membrane-enzyme target in tuberculosis drug discovery, interpreting the 2026 kinetic study while separating biochemical evidence from whole-cell and clinical validation. The article also positions Miransertib as a separate catalog resource rather than implying unsupported activity against WecA.

• CHIR-99021 (CT99021) HCl Product Overview

  2026-10-05

  CHIR-99021 (CT99021) HCl is an APExBIO-listed small-molecule GSK-3α/β inhibitor for conceptual research in cell signaling and stem-cell biology. No directly matched paper evidence was provided, so supplier claims should not be treated as independently validated findings.

• Norepinephrine-to-Angiotensin II Conversion Ratio

  2026-10-04

  A post-hoc analysis of the ARAMIS trial estimated a norepinephrine-to-angiotensin II conversion dose ratio of 10:1 when norepinephrine was expressed as bitartrate, or 5:1 as norepinephrine base. The study provides a clinically relevant framework for comparing vasopressor exposure, while its small, single-center observational design limits use of the ratio as a universal dosing rule.

• Promethazine HCl and Host-Directed Immunity

  2026-10-03

  A source-grounded perspective on how Promethazine HCl fits into host-directed antibacterial research, with emphasis on macrophage biology, evidence boundaries, translational study design, and product provenance.

• ATG4B Nuclear Translocation and AML DNA Repair

  2026-10-01

  This study identifies an energy-sensitive ATG4B–PRMT1–MRE11 axis that connects metabolic stress with defective DNA repair and leukemia progression. Its combination of mechanistic cell studies, genetically defined AML models, and patient-derived xenografts provides a useful framework for evaluating how metabolic state influences genomic stability, while requiring careful validation before transfer to other disease or drug-discovery settings.

• Rotigotine hydrochloride Assay Guide

  2026-10-01

  A scenario-based guide to using Rotigotine hydrochloride (SKU A3777) in cell viability, neuroprotection, proliferation, and cytotoxicity workflows. It connects concentration selection, solvent control, route-dependent interpretation, and vendor evaluation with product data and peer-reviewed Parkinson’s disease research.

• Sodium Citrate for Reproducible 3D SERS Arrays

  2026-10-01

  Sodium citrate provides a practical chemistry variable for tuning gold nanoparticle assembly on polymer-pen-lithography patterns. This workflow connects citrate-controlled dispersion and metal-ion coordination with reproducible 3D SERS substrate fabrication, while separating literature-demonstrated performance from recommended optimization experiments.

• Diuron C6731 for Reliable Cell Toxicology Assays

  2026-09-30

  This scenario-driven guide shows how Diuron (SKU C6731) can support more interpretable cell viability, proliferation, and cytotoxicity experiments. It connects formulation, assay compatibility, dose-response design, and recent evidence on JAK2/STAT1 signaling in Diuron-associated renal injury.

• Doxycycline Hyclate in MMP-2/9 BBB Research

  2026-09-29

  Doxycycline hyclate is a matrix metalloproteinases inhibitor that can function as a mechanistic probe in blood–brain barrier research. This article explains how to distinguish MMP-dependent protection from broader anti-inflammatory or antimicrobial effects when designing translational assays.

• MK-2206: From Akt Biology to Host Defense

  2026-09-29

  Akt signaling is increasingly recognized as a shared control point between tumor-cell survival and pathogen-driven immune modulation. This thought-leadership article examines how MK-2206 dihydrochloride can help translational researchers test the Akt–mTOR–IL-1Ra axis identified in Bordetella persistence, while distinguishing established product pharmacology from a still-developing host-pathogen hypothesis.

• v-Agatoxin-IVA Reveals Low-Affinity N-Type Blockade

  2026-09-28

  Sidach and Mintz showed that v-Agatoxin-IVA is highly potent for P-type calcium channels but can also inhibit N-type currents at micromolar concentrations. Their whole-cell recordings refine toxin-based channel classification and demonstrate why apparent selectivity must be interpreted alongside concentration, neuronal context, and voltage dependence.

• MK-2206 Dihydrochloride: Akt Assay Workflows

  2026-09-28

  Use MK-2206 dihydrochloride to test whether Akt activity contributes to cell survival, pathway responses, or treatment sensitivity—not simply to label cells as Akt-dependent. This workflow connects its cancer-research applications with a bone-cell study of glucocorticoid injury while clearly separating published findings from suggested pilot conditions.

• PBA-Modified PAD4 Inhibitors Suppress Tumors and NETs

  2026-09-27

  A 2023 study developed phenylboronic acid-modified PAD4 inhibitors to improve tumor-associated uptake and disrupt the PAD4–H3cit–NET pathway. Its lead compound, 5i, reduced tumor growth and metastatic outcomes in mouse models, supporting further investigation of tumor-directed PAD4 inhibition while leaving important questions about mechanism and translation unresolved.

• MK-571 (L-660,711) in Inflammation Assays

  2026-09-26

  Use MK-571 to separate cysteinyl-leukotriene receptor signaling from downstream inflammatory readouts, while keeping its distinct MRP1 activity in view. This practical guide covers receptor and transporter assay design, solvent controls, orthogonal validation, and what a quercetin bioavailability study can—and cannot—add to these experiments.

• Miltefosine: Context-Dependent Signaling in Cell Models

  2026-09-25

  Miltefosine is often described through a single pathway, but evidence spans PI3K/Akt signaling and Ras/MEK/ERK-dependent neutrophil differentiation. This article explains how to interpret that context dependence and design assays that distinguish pathway effects from cell-state outcomes.

8283 records 1/553 page Next 12345 下5页 Last page